Scribd Logo
Upload

Welcome to Scribd!

  • US Products - Current Age

    Uploaded by

    imtenanmedical
    2 views2 pages
    This report from Evaluate Ltd provides data on the top selling products in the US for Eli Lilly, including each product's name, age in the US market in years, 2022 and projected 2028 US sales in millions, and FDA approval date. Trulicity is Eli Lilly's top selling product at $5.7 billion currently, with an expected CAGR of -11% through 2028. The oldest product is Glucagon at 61.8 years and the newest is Bebtelovimab at 1.1 years on the US market. In total, Eli Lilly's current US sales from these products are $16.4 billion projected to reach $30.4 billion by 2028,

    Original Description:

    Copyright

    © © All Rights Reserved

    Available Formats

    XLSX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This report from Evaluate Ltd provides data on the top selling products in the US for Eli Lilly, including each product's name, age in the US market in years, 2022 and projected 2028 US sales in millions, and FDA approval date. Trulicity is Eli Lilly's top selling product at $5.7 billion currently, with an expected CAGR of -11% through 2028. The oldest product is Glucagon at 61.8 years and the newest is Bebtelovimab at 1.1 years on the US market. In total, Eli Lilly's current US sales from these products are $16.4 billion projected to reach $30.4 billion by 2028,

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    2 views2 pages

    US Products - Current Age

    Uploaded by

    imtenanmedical
    This report from Evaluate Ltd provides data on the top selling products in the US for Eli Lilly, including each product's name, age in the US market in years, 2022 and projected 2028 US sales in millions, and FDA approval date. Trulicity is Eli Lilly's top selling product at $5.7 billion currently, with an expected CAGR of -11% through 2028. The oldest product is Glucagon at 61.8 years and the newest is Bebtelovimab at 1.1 years on the US market. In total, Eli Lilly's current US sales from these products are $16.4 billion projected to reach $30.4 billion by 2028,

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    Source: Evaluate Ltd

    Report: US Products - Current Age


    Report Date Monday, August 28, 2023
    All Financial Data in US $ (mln)

    Rank Product US NME Age (Yrs)


    Eli Lilly 1 Trulicity 8.9
    2 Taltz 7.1
    3 Verzenio 5.9
    4 Bebtelovimab 1.1
    5 Humalog 26.2
    6 Humulin R 38.9
    7 Alimta 19.5
    8 Erbitux 19.5
    9 Basaglar 5.8
    10 Emgality 4.9
    11 Bamlanivimab & Etesevimab 4.1
    12 Forteo 20.7
    13 Mounjaro 1.3
    14 Cyramza 9.3
    15 Olumiant 5.2
    16 Retevmo 3.3
    17 Baqsimi 3.9
    18 Humatrope 36.3
    19 Cialis 19.4
    20 Cymbalta 18.8
    21 Zyprexa 25.0
    22 Glucagon (ELI) 61.8
    23 Reyvow 3.5
    24 Prozac 35.6
    25 Effient 13.9
    26 Evista 25.6
    27 Strattera 18.8
    28 Portrazza 7.7
    29 Symbyax 17.8
    mirikizumab
    Jaypirca 0.4
    Total 470

    Report Filters
    Company Eli Lilly
    Annual Sales USA Exclude blank or zero rows
    WW Market Status (Current) 3 Items
    Marketed Marketed
    Marketed Approved
    Marketed Withdrawn
    Note: Shaded Cells
    Annual Sales USA - Sales
    2022 2028 CAGR FDA Approval Date
    5,689 2,741 (11%) Sep 2014
    1,725 2,309 5% Mar 2016
    1,653 4,946 20% Sep 2017
    1,282 n/a Feb 2022
    1,192 629 (10%) Jun 1996
    730 575 (4%) Oct 1982
    544 29 (38%) Feb 2004
    500 314 (7%) Feb 2004
    471 430 (2%) Dec 2015
    463 616 5% Sep 2018
    377 n/a Feb 2019
    367 144 (14%) Nov 2002
    367 15,062 86% May 2022
    351 145 (14%) Apr 2014
    148 313 13% May 2018
    143 366 17% May 2020
    110 158 6% Jul 2019
    56 44 (4%) Oct 1986
    35 21 (8%) Nov 2003
    34 25 (5%) Aug 2004
    30 19 (8%) Sep 1996
    29 22 (4%) Nov 1960
    24 72 20% Oct 2019
    22 3 (28%) Dec 1987
    9 3 (16%) Jul 2009
    1 0 (11%) Dec 1997
    1 0 (16%) Nov 2002
    1 1 0 Nov 2015
    0 0 (56%) Dec 2003
    806 n/a
    651 n/a Jan 2023
    16,353 30,443 11%

    You might also like